The Life Sciences team advised Aura Biosciences, Inc. (Nasdaq: AURA) on its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aura, are expected to be $75.6 million. All of the shares are being offered by Aura. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Aura is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.

The Goodwin team was led by Stuart Cable, Danielle Lauzon, Stephanie Richards, Daniel Hughes, Amanda Rae Schwarzenbart, and Thomas Jackson (Corporate); and included Julie Tibbets and Elizabeth Mulkey (FDA/Regulatory); Roger Cohen, Simone Otenaike, and Nikhil Sethi (Healthcare); Sarah Bock and James Devendorf (ERISA & Executive Compensation); Dan Karelitz (Tax); Brad Smith (Employment); and Tim Worden and Lucy Sharples (UK Regulatory).

For more details, read the press release and articles in Endpoints, Fierce Biotech, and MarketWatch.